Navigation Links
Chernobyl Disaster still Causing Cancer

The Chernobyl disaster of two decades ago still holds more than a third of Britain prey to its deadly consequences. Its radioactivity contamination here still continues// to cause cancer in children according to the investigation led by the Independent on Sunday.

According to official measurements published in the report at least 34 per cent of Britain will continue to remain radioactive for centuries as a result of the disaster.

This has been especially noted in Cumbria the worst-affected part of England, where rates of thyroid cancer in children have risen by 12-fold after the catastrophe. This has disproved government assurances at the time that the radiation in Britain was "nowhere near the levels at which there is any hazard to health".

The report was presented at a conference at the Royal College of Surgeons. It cites official figures that show that most of the highly radioactive caesium emitted in the disaster was blown across Europe by winds.

Areas of about 81,000 sq km mainly in Northern Ireland, Scotland, Wales and the west of England - were contaminated above 4,000 bequerels per square meter. The doses of radiations from this are only expected to decline slowly over the next few centuries.

The rates of thyroid cancer in children across northern England before and after the Chernobyl cloud passed overhead were examined thoroughly by scientists at Newcastle University, led by Professor Louise Palmer. Their study has revealed slight increases across the region - and an abrupt 12-fold jump in Cumbria, which received most of the fall-out. The results have been found to be consistent with a causal association with the Chernobyl catastrophe.
'"/>




Page: 1

Related medicine news :

1. 20 Years Later: Chernobyl’s effects are indelible and lastin
2. Greenpeace Says 93,000 Extra Cancer Deaths Due To Chernobyl Fallout
3. AIDS Disaster in India is Imminent
4. Disaster Planning Guide From Harvard Health Publications
5. Chronic Post-Traumatic Stress Disorder (PTSD) Risk In Young Natural Disaster Survivors
6. Tsunami Unplugged: Natural Disasters Favor the Under-privileged
7. Bicycle-Powered Portable Water Filter System For Disaster Zones
8. PTST Mostly Seen Among Disaster Victims
9. Indian Railways Cannot Deal With Major Disasters
10. US Emergency Rooms ill prepared for Disasters
11. AAP Urges Families To Create Emergency Disaster Plans
Post Your Comments:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10